Sunshine Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
14/08/2025 22:01
Sunshine Biopharma Inc SBFM.OQ reported a quarterly adjusted loss of 39 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-9.94. The lone analyst forecast for the quarter was for a loss of 11 cents per share. Revenue rose 1.2% to $9.41 million from a year ago; analysts expected $11.20 million. Sunshine Biopharma Inc's reported EPS for the quarter was a loss of 39 cents. The company reported a quarterly loss of $1.77 million. Sunshine Biopharma Inc shares had risen by 4.2% this quarter and lost 50.0% so far this year. FORECAST CHANGES In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Sunshine Biopharma Inc is $7.00, about 78.6% above its last closing price of $1.50 This summary was machine generated from LSEG data August 14 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.11 | -0.39 | Missed |
| Dec. 31 2024 | 0.11 | -1.00 | Missed |
| Sep. 30 2024 | 9.00 | -0.94 | Missed |